Analysis Of M&A Performance Of FOSUN Pharmaceutical(Group)CO.,LTD Merged Alma Lasers

In recent years,with the rapid growth of our country's economy,many large pharmaceutical enterprises in our country have begun to carry out their own journey of globalization.At the same time,under the encouragement of national policies,overseas mergers and acquisitions of pharmaceutical enterprises are constantly emerging.People are increasingly concerned about whether overseas mergers and acquisitions can create value and the impact of cross-border M & A on business performance.The merger and acquisition performance of Fosun Pharma use case study method combined with comparative research and literature research.With the acquisition of the cause and effect as the theoretical basis,based on the acquisition of Fosun Pharma,analyse mergers and acquisitions Fosun Pharma relies on the way from syndrome merger,acquisition and process the payment of the price.In the aspect of M &A performance analysis,we use event study to explore the Alma Lasers super short-term market effect of Fosun Pharma,and explore the long-term financial performance of Fosun Pharma by EVA performance evaluation index.After that,based on the implementation effect and motivation of mergers and acquisitions behavior established evaluation system,compared with the industry internal growth model business model and the revival of Hengrui medicine medicine.Finally,this paper summarizes the financial performance of Alma Lasers by the merger and acquisition of the compound star medicine and summarizes the experience and enlightenment of the M & A.Through the research of Fosun Pharma's M & A performance,we can draw the following conclusions:(1)Increase in mergers and acquisitions Fosun Pharma plus short-term shareholder wealth,in the long-term financial performance,EVA index since 2013 has been leapfrog growth.(2)Fosun's M & A has gained the advantage of scale.To some extent,it has realized the synergy effect of operation and management,but also brought liquidity risk to enterprises.The financial policy is more radical and the short-term debt paying ability of enterprises is weaker.(3)Through the integration of the acquirers,Fosun Pharma is based on the development goal of the medical device industry,but still lacks the core competitiveness of the company's long-term development.I hope this article can make a little contribution to the application of EVA in the value evaluation of Listed Companies in China and provide useful reference for the merger and acquisition of pharmaceutical enterprises,especially the transnational merger and acquisition.